The Effect of Maximum Body Weight in Lifetime on the Development of Type 2 Diabetes

Diabetes Clinical Trial

— MAXWEL  

Official title:

Study of MAXimum Weight in Lifetime on Glucose Homeostasis (MAXWEL)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00816608
• Other study ID #: MAXWEL 09
• Status: Completed
• Phase: N/A
• First received: December 31, 2008
• Last updated: October 24, 2013
• Start date: August 2006
• Est. completion date: September 2013

Study information

• Verified date: October 2013
• Source: Seoul National University Bundang Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Korea: Food and Drug Administration
• Study type: Observational

Clinical Trial Summary

Hypothesis : The maximum body weight in lifetime is associated with the onset of development of type 2 diabetes.

Description:

Obesity is well recognized risk factor for type 2 diabetes. Recent studies reported that weight change, especially severe weight gain was associated with an increased risk of type 2 diabetes. The aim of this study is to investigate whether the maximum body weight of lifetime is associated with the early onset of type 2 diabetes or an increased risk of type 2 diabetes in Korean.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 3000
• Est. completion date: September 2013
• Est. primary completion date: December 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• Korean with type 2 diabetes

• Korean with confirmed IFG or IGT

• Korean with NGT

Exclusion Criteria:

• Malignancy except thyroid cancer

• Active tuberculosis

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Diabetes
• Glucose Intolerance
• Prediabetes
• Prediabetic State

Locations

Country	Name	City	State
Korea, Republic of	Seoul National University Bundang Hospital	Seongnam	Bundang-gu

Sponsors (1)

Lead Sponsor	Collaborator
Seoul National University Bundang Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The development of diabetes		Five years	No
Secondary	DM complication		5 years	No